I've never implicitly handicapped the three trials. I merely pointed out that, of the 3 trials, Eyeguard B is the only one with Ph2 results which introduces an additional risk factor to the investment decision. For the record, I agree with your and iwfal's assessment.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.